In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events | ACP Diabetes Monthly
The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.
DPP-4 inhibitors are less effective than metformin for reducing hemoglobin A1c | ACP Diabetes Monthly
A meta-analysis of randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to metformin and other drugs found that DPP-4 monotherapy is less effective.
Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients | ACP Diabetes Monthly
More than 20% of patients with type 2 diabetes received treatment more intensive than that recommended by HbA1c-based guidelines, a study of Medicare patients found.
Intensive weight management in primary care improved weight loss and remission of type 2 diabetes | ACP Diabetes Monthly
The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality | ACP Diabetes Monthly
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
Intensive control of blood pressure reduced incidence of retinopathy, but not progression of established retinopathy, in patients with type 1 or 2 diabetes, according to an analysis of 15 randomized controlled trials.
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization | ACP Diabetes Monthly
If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.
Bariatric surgery improved HbA1c at 5 y more than intensive medical care alone in obese patients with T2DM | ACP Diabetes Monthly
A commentary considers the industry-funded STAMPEDE trial, in which obese patients with type 2 diabetes were randomly assigned to intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.
Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes | ACP Diabetes Monthly
A meta-analysis included 67 randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to placebo or other oral antidiabetic agents.
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y | ACP Diabetes Monthly
A subanalysis of a trial of empagliflozin for patients with cardiovascular disease (CVD) found lower rates of nephropathy in those randomized to empagliflozin rather than placebo.